Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
May 17, 2024
At a time when global challenges appear daunting and geopolitical rivalries are rising, it is useful to remind ourselves that the past 75 years have seen more improvement in the human condition than ever before. Fifty years ago, half the world lived in extreme poverty, today it is less than one in 1...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...
Blog Post
May 22, 2023
This week, the African Development Bank (AfDB) will hold its annual meeting in Sharm El Sheikh, Egypt. This is the right moment for its shareholders and other donors to commit to allocating some of their excess Special Drawing Rights (SDRs) to the hybrid capital fund that the AfDB has proposed to ...
Blog Post
February 20, 2023
On Sunday February 19th, the 36th Assembly of Heads of State and Government of the African Union elected Dr Jean Kaseya, a public health physician from the Democratic Republic of Congo, as the new Director General of the Africa Centres for Disease Control and Prevention (Africa CDC). Dr Kaseya will ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 02, 2022
An important debate is taking place in Europe right now on how to fund new antimicrobials. For months it has been speculated that the European Union may move towards implementing transferable exclusivity vouchers (TEVs). In response, 14 Member States wrote to the European Commission outlining why th...